Guardant Reports Record Q3 Sales And A Buy Back From Softbank
Executive Summary
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.
You may also be interested in...
JPM 2022 Mid-Week IVD Roundup: Guardant, Illumina, Ortho Clinical, Thermo Fisher
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Dexcom’s G7 Expands Globally After A Long Wait
Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.
Novartis Heart Health Catalyst Announces Dual Winners
PocDoc and Lifelight have won the Novartis’ Heart Health Catalyst program and will work together on a tool combining smartphone-based and lipid-measuring tools for monitoring cardiac health on a population level.